Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Gastroblastoma in Adulthood-A Rarity among Rare Cancers-A Case Report and Review of the Literature.

Centonze G, Mangogna A, Salviato T, Belmonte B, Cattaneo L, Monica MAT, Garzone G, Brambilla C, Pellegrinelli A, Melotti F, Testi A, Monti V, Kankava K, Gasparini P, Dagrada G, Mazzaferro V, Cotsoglou C, Collini P, Pruneri G, Milione M.

Case Rep Pathol. 2019 Nov 28;2019:4084196. doi: 10.1155/2019/4084196. eCollection 2019.

2.

Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.

Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S.

Mod Pathol. 2020 Feb;33(2):217-227. doi: 10.1038/s41379-019-0371-0. Epub 2019 Sep 30.

PMID:
31570769
3.

Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.

Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J.

Lancet Oncol. 2019 Sep;20(9):1252-1262. doi: 10.1016/S1470-2045(19)30319-5. Epub 2019 Jul 19. Erratum in: Lancet Oncol. 2019 Oct;20(10):e559.

PMID:
31331701
4.

NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas.

Brenca M, Stacchiotti S, Fassetta K, Sbaraglia M, Janjusevic M, Racanelli D, Polano M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, Gronchi A, Astolfi A, Indio V, Pantaleo MA, Picci P, Casali PG, Dei Tos AP, Pilotti S, Maestro R.

J Pathol. 2019 Sep;249(1):90-101. doi: 10.1002/path.5284. Epub 2019 May 14.

5.

Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study.

Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG.

Eur J Cancer. 2019 Jan;106:225-233. doi: 10.1016/j.ejca.2018.10.024. Epub 2018 Dec 5.

PMID:
30528807
6.

The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.

Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, Stacchiotti S, Sensi M, Canevari S, Pilotti S.

Cancer Commun (Lond). 2018 Nov 28;38(1):70. doi: 10.1186/s40880-018-0339-3.

7.

Self-Assembled Nanomicelles as Curcumin Drug Delivery Vehicles: Impact on Solitary Fibrous Tumor Cell Protein Expression and Viability.

Dagrada G, Rupel K, Zacchigna S, Tamborini E, Pilotti S, Cavalleri A, Fechner LE, Laurini E, Smith DK, Brich S, Pricl S.

Mol Pharm. 2018 Oct 1;15(10):4689-4701. doi: 10.1021/acs.molpharmaceut.8b00655. Epub 2018 Sep 17.

PMID:
30179512
8.

Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma.

Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada GP, Colombo C, Gronchi A, Pession A, Casali PG, Stacchiotti S, Pantaleo MA.

Int J Mol Sci. 2018 Jun 23;19(7). pii: E1855. doi: 10.3390/ijms19071855.

9.

Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor.

Provenzano S, Raimondi A, Bertulli RM, Colia V, Renne SL, Collini P, Dagrada G, Callegaro D, Fiore M, Greco FG, Casali PG.

Clin Sarcoma Res. 2017 Dec 28;7:20. doi: 10.1186/s13569-017-0086-2. eCollection 2017.

10.

Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue.

Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, Gronchi A, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA.

Oncotarget. 2017 May 17;8(36):60036-60045. doi: 10.18632/oncotarget.17958. eCollection 2017 Sep 1.

11.

HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma.

Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, Gronchi A, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession A, Biasco G, Casali PG, Stacchiotti S.

Genes Chromosomes Cancer. 2017 Jul;56(7):582-586. doi: 10.1002/gcc.22462. Epub 2017 May 4.

PMID:
28383167
12.

Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

Stacchiotti S, Saponara M, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, Gronchi A, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N.

Eur J Cancer. 2017 May;76:84-92. doi: 10.1016/j.ejca.2017.02.002. Epub 2017 Mar 8.

PMID:
28284173
13.

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.

Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini CM, D'Incalci M, Gatta R.

BMC Cancer. 2017 Feb 6;17(1):107. doi: 10.1186/s12885-017-3091-1.

14.

A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.

Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L.

Eur J Cancer. 2016 Dec;69:158-165. doi: 10.1016/j.ejca.2016.09.022. Epub 2016 Nov 5.

PMID:
27821319
15.

Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.

Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C.

J Invest Dermatol. 2017 Feb;137(2):484-493. doi: 10.1016/j.jid.2016.06.634. Epub 2016 Sep 5.

16.

Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework.

Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, Belfiore A, Perrone F, Gualeni AV, Gloghini A, Cabras A, Brenca M, Maestro R, Zaffaroni N, Casali P, Bertulli R, Deraco M, Pilotti S.

Oncotarget. 2016 Nov 15;7(46):75503-75517. doi: 10.18632/oncotarget.12262.

17.

Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.

Cassinelli G, Favini E, Dal Bo L, Tortoreto M, De Maglie M, Dagrada G, Pilotti S, Zunino F, Zaffaroni N, Lanzi C.

Oncotarget. 2016 Jul 26;7(30):47848-47863. doi: 10.18632/oncotarget.10292.

18.

Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.

Stacchiotti S, Provenzano S, Dagrada G, Negri T, Brich S, Basso U, Brunello A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, Gronchi A, Dei Tos AP, Crippa F, Morosi C, Pilotti S, Casali PG.

Ann Surg Oncol. 2016 Sep;23(9):2735-44. doi: 10.1245/s10434-016-5331-z. Epub 2016 Jun 22.

PMID:
27334221
19.

Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma.

Perrone F, Bossi P, Cortelazzi B, Dagrada GP, Paielli N, Licitra L, Pilotti S.

Oral Oncol. 2016 Jul;58:e4-5. doi: 10.1016/j.oraloncology.2016.05.015. Epub 2016 Jun 1. No abstract available.

PMID:
27262592
20.

Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss.

Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R.

Mol Cancer Res. 2016 Sep;14(9):820-9. doi: 10.1158/1541-7786.MCR-16-0068. Epub 2016 Jun 2.

21.

Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).

Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG.

Clin Cancer Res. 2016 Feb 15;22(4):837-46. doi: 10.1158/1078-0432.CCR-15-1243. Epub 2015 Aug 10.

22.

Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S.

Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.

23.

Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.

Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP, Pilotti S.

Am J Surg Pathol. 2015 Mar;39(3):383-93. doi: 10.1097/PAS.0000000000000366.

PMID:
25581729
24.

Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.

Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G, Quattrone P, Bergamini C, Potepan P, Civelli E, Fallai C, Pilotti S, Licitra L.

Head Neck. 2016 May;38(5):724-31. doi: 10.1002/hed.23940. Epub 2015 Jun 25.

PMID:
25522335
25.

Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.

Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N.

Eur J Cancer. 2014 Nov;50(17):3021-8. doi: 10.1016/j.ejca.2014.09.004. Epub 2014 Sep 27.

PMID:
25269954
26.

Identification of a gene expression driven progression pathway in myxoid liposarcoma.

De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S.

Oncotarget. 2014 Aug 15;5(15):5965-77.

27.

Activity of sunitinib in extraskeletal myxoid chondrosarcoma.

Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG.

Eur J Cancer. 2014 Jun;50(9):1657-64. doi: 10.1016/j.ejca.2014.03.013. Epub 2014 Apr 2.

PMID:
24703573
28.

Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.

Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, Gronchi A, Panizza P, Pierotti MA, Tamborini E, Pilotti S.

Neuro Oncol. 2014 Jan;16(1):72-80. doi: 10.1093/neuonc/not238.

29.

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.

Stacchiotti S, Dagrada GP, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, Gronchi A, Dei Tos AP, Pilotti S, Casali PG.

Clin Sarcoma Res. 2013 Dec 18;3(1):16. doi: 10.1186/2045-3329-3-16.

30.

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib.

Stacchiotti S, Dagrada GP, Morosi C, Negri T, Romanini A, Pilotti S, Gronchi A, Casali PG.

Clin Sarcoma Res. 2012 Oct 11;2(1):22. doi: 10.1186/2045-3329-2-22.

31.

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.

Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group.

Clin Cancer Res. 2011 Dec 15;17(24):7776-84. doi: 10.1158/1078-0432.CCR-11-1791. Epub 2011 Oct 12.

32.

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.

Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group.

Genes Chromosomes Cancer. 2011 Oct;50(10):765-74.

PMID:
21961181
33.

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group.

Leukemia. 2012 Feb;26(2):349-55. doi: 10.1038/leu.2011.204. Epub 2011 Aug 12.

34.

Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.

Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Davies FE, Morgan GJ.

Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1703-7. doi: 10.1158/1055-9965.EPI-11-0157. Epub 2011 Jun 15.

35.

Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma.

Tapper W, Chiecchio L, Dagrada GP, Konn ZJ, Stockley DM, Szubert AJ, Gregory WM, Bell SE, Jackson GH, Child JA, Morgan GJ, Ross FM.

J Clin Oncol. 2011 Jan 10;29(2):e37-9; author reply e40-1. doi: 10.1200/JCO.2010.31.0516. Epub 2010 Dec 6. No abstract available.

PMID:
21135272
36.

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ.

Blood. 2010 Oct 14;116(15):e56-65. doi: 10.1182/blood-2010-04-279596. Epub 2010 Jul 8.

PMID:
20616218
37.

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Ross FM, Chiecchio L, Dagrada G, Protheroe RK, Stockley DM, Harrison CJ, Cross NC, Szubert AJ, Drayson MT, Morgan GJ; UK Myeloma Forum.

Haematologica. 2010 Jul;95(7):1221-5. doi: 10.3324/haematol.2009.016329. Epub 2010 Apr 21.

38.

Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum.

Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064.

39.

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.

Chiecchio L, Dagrada GP, Protheroe RK, Stockley DM, Smith AG, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum.

Haematologica. 2009 Jul;94(7):1024-8. doi: 10.3324/haematol.2008.004440. Epub 2009 May 19.

40.

Frequent upregulation of MYC in plasma cell leukemia.

Chiecchio L, Dagrada GP, White HE, Towsend MR, Protheroe RK, Cheung KL, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum.

Genes Chromosomes Cancer. 2009 Jul;48(7):624-36. doi: 10.1002/gcc.20670.

PMID:
19396865
41.

Deletions of CDKN2C in multiple myeloma: biological and clinical implications.

Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ.

Clin Cancer Res. 2008 Oct 1;14(19):6033-41. doi: 10.1158/1078-0432.CCR-08-0347.

42.

TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.

Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, Licitra L, Pilotti S.

Transl Oncol. 2008 Sep;1(3):121-8.

43.

Neuroendocrine small cell carcinoma of the cervix associated with endocervical adenocarcinoma: a case report.

Alphandery C, Dagrada G, Frattini M, Perrone F, Pilotti S.

Acta Cytol. 2007 Jul-Aug;51(4):589-93.

PMID:
17718130
44.

Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.

Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ.

Blood. 2007 Nov 1;110(9):3291-300. Epub 2007 Jul 3.

PMID:
17609426
45.

Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.

Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, Gronchi A, Perrone F, Carbone A, Pierotti MA, Casali PG, Pilotti S.

Clin Cancer Res. 2006 Dec 1;12(23):6920-8.

46.

Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma.

Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, Bossi P, Staurengo S, Oggionni M, Locati L, Cantu G, Squadrelli M, Carbone A, Pierotti MA, Pilotti S.

Clin Cancer Res. 2006 Nov 15;12(22):6643-51. Erratum in: Clin Cancer Res. 2007 Jul 15;13(14):4313.

47.

Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.

Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, Cabanas ED, Parker T, Nightingale M, Wechalekar A, Orchard KH, Harrison CJ, Cross NC, Morgan GJ, Ross FM.

Leukemia. 2006 Sep;20(9):1610-7. Epub 2006 Jul 6.

PMID:
16826223
48.

PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.

Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, Pierotti MA, Pilotti S.

J Pathol. 2006 Apr;208(5):615-23.

PMID:
16470538
49.

9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.

Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, Gronchi A, Pierotti MA, Pilotti S.

Cancer. 2005 Jul 1;104(1):159-69.

50.

Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer.

Locati LD, Rinaldi G, Bossi P, Dagrada GP, Quattrone P, CantĂș G, Licitra L.

Oral Oncol. 2005 Jan;41(1):97-8. No abstract available.

PMID:
15598592

Supplemental Content

Loading ...
Support Center